Regulation of antibody immunotherapy by fine-tuning FcR interactions

Posted by

SELECTBIO

Mark Cragg, Professor, University of Southampton

Abstract
Monoclonal antibodies (mAb) represent a growing class of 'block-buster' cancer drugs and so understanding of their modes of action is critical. Here, we present evidence that different mAb interact with Fc receptors differently in order to achieve their therapeutic activities.